AKT1 and breast cancer: Expression of a transient transfected HER3 in the SKBR3 cells prevented this decline, indicating that heterodimerization and crosstalk between HER2 and HER3 might be important in mediating the downstream pathway that leads to Akt activation in breast cancer cells after treatment with doxorubicin.